Virtu Financial LLC Invests $251,000 in Repligen Co. (NASDAQ:RGEN)

Virtu Financial LLC bought a new stake in Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,744 shares of the biotechnology company’s stock, valued at approximately $251,000.

Other institutional investors also recently added to or reduced their stakes in the company. Ballentine Partners LLC raised its holdings in shares of Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc increased its holdings in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares during the last quarter. MML Investors Services LLC increased its holdings in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares during the last quarter. GAMMA Investing LLC raised its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 2.7 %

Shares of Repligen stock opened at $133.41 on Friday. The company has a 50-day moving average of $154.21 and a two-hundred day moving average of $148.14. The stock has a market cap of $7.49 billion, a PE ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $184.98.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, research analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the topic of a number of recent analyst reports. Royal Bank of Canada increased their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Finally, StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Repligen presently has a consensus rating of “Hold” and a consensus price target of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.